Compare NECB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | CERS |
|---|---|---|
| Founded | 1934 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.2M | 276.0M |
| IPO Year | 2021 | 1996 |
| Metric | NECB | CERS |
|---|---|---|
| Price | $24.56 | $2.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 31.3K | ★ 1.3M |
| Earning Date | 04-24-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ 3.25 | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $4.85 | $19.95 |
| Revenue Next Year | $8.45 | $8.84 |
| P/E Ratio | $7.70 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $19.27 | $1.15 |
| 52 Week High | $25.65 | $2.96 |
| Indicator | NECB | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 57.94 |
| Support Level | $22.34 | $1.93 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.54 | 0.09 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 79.15 | 93.85 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.